Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
5-Amino-1MQ vs Exenatide (Byetta / Bydureon)
An educational, source-based comparison of 5-Amino-1MQ and Exenatide (Byetta / Bydureon) — how each peptide works, what it's researched for, and what to know before going deeper.
Not a peptide but commonly grouped in peptide research. A selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Inhibition increases SAM and NAD+ availability, increasing adipocyte energy expenditure in animal models.
- Diet-induced obesity (rodent)
- White adipose tissue energy expenditure
- Age-related muscle function
- • Investigational; no human clinical trials yet.
- • Not FDA-approved.
First-in-class GLP-1 receptor agonist for type 2 diabetes.
Synthetic version of exendin-4 (originally from Gila monster saliva). Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and increase satiety.
- Type 2 diabetes
- Weight management (off-label)
- • FDA-approved.
- • Nausea common; pancreatitis warning.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibition reduces adiposity in obese mice | Nature Medicine | 2015 | Demonstrated weight loss and improved metabolic profile via NNMT inhibition. |
| Exenatide (Byetta / Bydureon) | EXSCEL trial | NEJM | 2017 | Cardiovascular safety established for once-weekly exenatide. |
Side-effect & safety grid
- Investigational; no human clinical trials yet.
- Not FDA-approved.
- FDA-approved.
- Nausea common; pancreatitis warning.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
5-Amino-1MQ vs Exenatide (Byetta / Bydureon) — Key differences
- Class: 5-Amino-1MQ is classified as Metabolic · Small Molecule, while Exenatide (Byetta / Bydureon) is GLP-1 Agonist · Metabolic.
- Primary research focus: 5-Amino-1MQ — diet-induced obesity (rodent); Exenatide (Byetta / Bydureon) — type 2 diabetes.
- Tag: Metabolic vs FDA-Approved · Metabolic.